IQVIA's Growth Setup Looks Positive After Q1 Beat, RBC Says

MT Newswires Live05-07

IQVIA (IQV) posted better-than-expected Q1 revenue and EPS, reinforcing contract research organization recovery thesis, RBC Capital Markets said in a note Tuesday.

"We believe the setup is positive," the report said, pointing to

accelerated organic growth, AI tailwind, and mid-to-high single digits growth in forward-looking demand indicators.

The note pointed to improving growth in Commercial, driven in part by strength in Patient Solutions and analytics & consulting.

The report said it reflects large pharma deploying capital towards late-stage assets with the highest probability of success.

AI-enabled offerings are also gaining traction, with clients selecting IQVIA to build AI-ready data foundations and record pipelines in analytics & consulting, the report added.

RBC kept its outperform rating and $221 price target.

Price: 177.38, Change: +0.96, Percent Change: +0.54

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment